These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 25802928

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Bioanalysis of therapeutic peptides: differentiating between total and anti-drug antibody bound drug using liquid chromatography-tandem mass spectrometry quantitation.
    Heinig K, Wirz T, Schick E, Guenzi A.
    J Chromatogr A; 2013 Nov 05; 1316():69-77. PubMed ID: 24119751
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Innovative use of LC-MS/MS for simultaneous quantitation of neutralizing antibody, residual drug, and human immunoglobulin G in immunogenicity assay development.
    Jiang H, Xu W, Titsch CA, Furlong MT, Dodge R, Voronin K, Allentoff A, Zeng J, Aubry AF, DeSilva BS, Arnold ME.
    Anal Chem; 2014 Mar 04; 86(5):2673-80. PubMed ID: 24506335
    [Abstract] [Full Text] [Related]

  • 7. The pharmacological chaperone AT2220 increases recombinant human acid α-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease.
    Khanna R, Flanagan JJ, Feng J, Soska R, Frascella M, Pellegrino LJ, Lun Y, Guillen D, Lockhart DJ, Valenzano KJ.
    PLoS One; 2012 Mar 04; 7(7):e40776. PubMed ID: 22815812
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Oral administration of recombinant human acid α-glucosidase reduces specific antibody formation against enzyme in mouse.
    Ohashi T, Iizuka S, Shimada Y, Eto Y, Ida H, Hachimura S, Kobayashi H.
    Mol Genet Metab; 2011 May 04; 103(1):98-100. PubMed ID: 21320791
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Simultaneous Quantification of Adalimumab and Infliximab in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry.
    Jourdil JF, Némoz B, Gautier-Veyret E, Romero C, Stanke-Labesque F.
    Ther Drug Monit; 2018 Aug 04; 40(4):417-424. PubMed ID: 29608486
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies.
    Stubenrauch K, Wessels U, Essig U, Vogel R, Schleypen J.
    J Pharm Biomed Anal; 2010 Jun 05; 52(2):249-54. PubMed ID: 20083366
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Lipidic Nanoparticles Comprising Phosphatidylinositol Mitigate Immunogenicity and Improve Efficacy of Recombinant Human Acid Alpha-Glucosidase in a Murine Model of Pompe Disease.
    Schneider JL, Dingman RK, Balu-Iyer SV.
    J Pharm Sci; 2018 Mar 05; 107(3):831-837. PubMed ID: 29102549
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line.
    Martiniuk F, Chen A, Donnabella V, Arvanitopoulos E, Slonim AE, Raben N, Plotz P, Rom WN.
    Biochem Biophys Res Commun; 2000 Oct 05; 276(3):917-23. PubMed ID: 11027569
    [Abstract] [Full Text] [Related]

  • 17. Monitoring cardiac function by B-type natriuretic peptide (BNP) in patients with infantile Pompe's disease treated with recombinant alpha-glucosidase.
    Hahn A, Schmidt D, Hagel KJ, Neubauer BA, Katz N.
    Clin Lab; 2006 Oct 05; 52(11-12):615-9. PubMed ID: 17175893
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease.
    An Y, Young SP, Kishnani PS, Millington DS, Amalfitano A, Corz D, Chen YT.
    Mol Genet Metab; 2005 Aug 05; 85(4):247-54. PubMed ID: 15886040
    [Abstract] [Full Text] [Related]

  • 20. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
    Raben N, Fukuda T, Gilbert AL, de Jong D, Thurberg BL, Mattaliano RJ, Meikle P, Hopwood JJ, Nagashima K, Nagaraju K, Plotz PH.
    Mol Ther; 2005 Jan 05; 11(1):48-56. PubMed ID: 15585405
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.